BridgeBio Stock Surges on Dwarfism Drug Data. It’s Bad News for BioMarin.
Text size BridgeBio stock is soaring Monday. Dreamstime BridgeBio Pharma stock was soaring after the biopharmaceutical company reported positive results in a Phase two clinical trial for an experimental treatment for achondroplasia, the most common type of short-limbed dwarfism. On Monday, BridgeBio (ticker: BBIO) said in a news release that its experimental drug Infigratinib showed … Read more